Methods of Controlling the Formation of Disulfide Bonds in Protein Solutions

Abstract

Disclosed herein are methods that have been developed to control the formation of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess. Also disclosed are protein solution parameters that allow for controlling the formation of disulfide bonds. In one example, the methods disclosed herein can be used to control the proportion of half antibody molecules in an antibody solution.

1 . A method of controlling the number of disulfide bonds between polypeptides of a multimeric protein produced by a bioprocess, the method comprising:
 contacting the polypeptides with a conditioned solution at a specific time point during the bioprocess;   wherein the conditioned solution comprises one or more predetermined solution parameters, and   incubating the conditioned solution comprising the polypeptides for a predetermined time at a predetermined temperature;   wherein the incubation of the polypeptides with the conditioned solution controls the formation of disulfide bonds between the polypeptides of the protein.   
     
     
         2 . The method of  claim 1 , wherein the number of disulfide bonds between the polypeptides of the protein is increased. 
     
     
         3 . The method of  claim 1 , wherein the number of disulfide bonds between the polypeptides of the protein is decreased. 
     
     
         4 . The method of  claim 1 , wherein the number of disulfide bonds between the polypeptides of the protein is maintained. 
     
     
         5 . The method of  claim 1 , wherein the predetermined solution parameters comprise one or more of: redox reagent identity, redox reagent concentration, pH, gas identity, dissolved gas levels, conductivity, and viable cell density. 
     
     
         6 . The method of  claim 5 , wherein the redox reagent identity is 2-mercaptoethylamine (2-MEA), reduced glutathione, oxidized glutathione, 2-mercaptoethanol, dithiothreitol (DTT), cysteine, cystine, dithiobutylamine, or sodium sulfite. 
     
     
         7 . The method of  claim 6 , wherein the redox reagent identity is 2-mercaptoethylamine (2-MEA). 
     
     
         8 . The method of  claim 6 , wherein the ratio of redox reagent molarity to protein molarity is at least about 4:1, 8:1, 16:1, or 32:1. 
     
     
         9 . The method of  claim 1 , wherein the predetermined temperature of the incubation is between about 2° C. and about 23° C. 
     
     
         10 . The method of  claim 1 , wherein the predetermined temperature of the incubation is between about 23° C. and about 37° C. or higher. 
     
     
         11 . The method of  claim 1 , wherein the conditioned solution comprising the polypeptides is mixed during incubation. 
     
     
         12 . The method of  claim 1 , further comprising:
 removing the polypeptides from the bioprocess at the specific time point during the bioprocess.   
     
     
         13 . The method of  claim 12 , further comprising:
 returning the polypeptides to the bioprocess after incubation.   
     
     
         14 . The method of  claim 1 , wherein the bioprocess comprises a batch, semi-continuous, or continuous bioprocess. 
     
     
         15 . The method of  claim 1 , wherein the specific time point during the bioprocess comprises a time point after a bioreactor operation or fed batch cell culture operation in the bioprocess. 
     
     
         16 . The method of  claim 1 , wherein the specific time point during the bioprocess comprises a time point wherein the polypeptides are in a solution comprising a plurality of cells. 
     
     
         17 . The method of  claim 16 , wherein the specific time point during the bioprocess comprises a time point wherein the polypeptides are located in a bioreactor, holding tank, or a non-bioreactor unit operation vessel comprising a plurality of cells. 
     
     
         18 . The method of  claim 1 , wherein the specific time point during the bioprocess comprises a time point wherein the polypeptides are in a cell-free solution. 
     
     
         19 . The method of  claim 18 , wherein the specific time point during the bioprocess comprises a time point wherein the polypeptides are located in a holding tank. 
     
     
         20 . The method of  claim 18 , wherein the specific time point during the bioprocess comprises a time point during the step of viral inactivation, adjustment, chromatography, filtration, dilution, concentration, or any bioprocess step that is cell-free. 
     
     
         21 . The method of  claim 18 , wherein the specific time point during the bioprocess comprises a time point during the clarification stage, clarified harvest stage, capture stage, intermediate chromatography stage, or polishing chromatography stage of the bioprocess. 
     
     
         22 . The method of  claim 18 , wherein the cell-free solution comprises clarified harvest. 
     
     
         23 . The method of  claim 18 , wherein the cell-free solution comprises Protein A eluate. 
     
     
         24 . The method of  claim 1 , wherein the multimeric protein is a non-antibody protein. 
     
     
         25 . The method of  claim 1 , wherein the multimeric protein is an antibody. 
     
     
         26 . The method of  claim 1 , wherein the multimeric protein is an antibody fragment. 
     
     
         27 . The method of  claim 25 , wherein the polypeptides of the multimeric protein comprise heavy chain polypeptides. 
     
     
         28 . The method of  claim 25 , wherein the polypeptides of the multimeric protein comprise light chain polypeptides. 
     
     
         29 . The method of  claim 25 , wherein the polypeptides of the multimeric protein comprise heavy chain polypeptides and light chain polypeptides. 
     
     
         30 . The method of  claim 1 , wherein the polypeptides are monomers or multimers of the protein. 
     
     
         31 . A method of controlling the proportion of half antibody molecules in a solution comprising a population of antibody molecules, the method comprising:
 contacting the solution comprising the population of antibody molecules with a conditioned solution;   wherein the conditioned solution comprises predetermined solution parameters; and   incubating the conditioned solution comprising the antibody molecules for a predetermined time at a predetermined temperature;   wherein the incubation of the antibody molecules with the conditioned solution controls the proportion of half antibody molecules in the conditioned antibody solution.   
     
     
         32 . The method of  claim 31 , wherein the predetermined solution parameters comprise redox reagent selection, redox reagent concentration, pH, gas selection, dissolved gas levels, conductivity, viable cell density, or protein concentration. 
     
     
         33 . The method of  claim 31 , wherein the antibody is an IgG4 antibody. 
     
     
         34 . The method of  claim 31 , wherein the antibody is an antibody fragment. 
     
     
         35 . The method of  claim 34 , wherein the antibody fragment is an IgG4 antibody fragment. 
     
     
         36 . The method of  claim 31 , wherein the proportion of half antibody molecules in the conditioned antibody solution is less than 30 percent. 
     
     
         37 . The method of  claim 31 , wherein the proportion of half antibody molecules in the conditioned antibody solution is less than 15 percent. 
     
     
         38 . The method of  claim 33 , wherein the antibody solution comprises natalizumab, gemtuzumab, or fresolimumab.